CellCarta has a long history of working with its biopharmaceutical partners to support oncology programs.
With our deep scientific expertise across multiple platforms, we are uniquely positioned to support targeted assays development for exploratory, secondary, and primary endpoints as well as the deployment of those assays in clinical trials.
Through its immuno-monitoring capabilities, including
CellCarta provides unmatched expertise to support the development of cancer immune therapies, including:
Our team of scientists successfully developed flow cytometry assays to measure a variety of immune checkpoint proteins in cryopreserved PBMC and whole blood, including PD-1, LAG-3, and PD-L1.
Other assays were developed for this platform including one to monitor receptor occupancy of therapeutic antibodies.
CellCarta offers access to world-class histopathology and molecular pathology services, for the development of clinical biomarkers and companion diagnostics.
Various immunotherapy biomarkers were already developed and validated by our team for rapid and productive immunohistochemistry (IHC) assays.
Digital pathology and all the technologies it offers might be well suited for the analysis of cancer and immune cells in clinical research.
However, many of these technologies face hurdles, including the validation process.
Our team developed a roadmap that navigates the validation methodologies that can be used for oncology clinical development, specifically immunotherapies.
Leveraging an outstanding combination of state-of-the-art mass spectrometry platforms and expertise in cell biology and bioinformatics,
CellCarta uses robust and proven proteomic approaches to identify neo-epitopes, drug targets, and candidate biomarkers.
Our MRM platform was used in several projects investigating correlations between clinical outcomes and presence of biomarkers, which led to the identification of several potential biomarkers.
Using the same MRM platform, CellCarta develops highly quantitative and specific mass spectrometry-based bioanalytical assays for the measurement of biomarkers and biotherapeutics, in support to clinical and pharmacokinetic (PK) studies.
We can monitor the expression of soluble B-cell maturation antigen (BCMA) in plasma samples and measure clinically relevant biomarkers in readily available formalin-fixed paraffin embedded (FFPE) samples.
We also have a proven track record of using mass spectrometry for the development of commercialized diagnostics, including a non-invasive blood-based diagnostic test to identify benign lung nodules.
Here are some examples of work we did in the field of oncology:
Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells.
Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition.
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.